Neurocrine Biosciences Rises on FDA Nod for CAH Drug

Investing42minutes ago

Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential

Analyst UpgradesDec 16 09:10 ET

TD Cowen Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $165

Moomoo NewsDec 16 08:33 ET · Ratings

CCORF Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $167

Moomoo NewsDec 16 08:33 ET · Ratings

Wedbush Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Cuts Target Price to $148

Moomoo NewsDec 16 08:33 ET · Ratings

Express News | Wedbush Reiterates Outperform on Neurocrine Biosciences, Maintains $148 Price Target

BenzingaDec 16 08:25 ET